IsoTis snaps up GenSci after Osteotech settlement
This article was originally published in Clinica
The sales and marketing synergies offered by a merger with GenSci OrthoBiologics and underlying industry growth should lead to IsoTis reaching profitability in 2005. So said the Swiss-Dutch company said after announcing its intention to acquire the Irvine, California operating subsidiary of Toronto, Canada-based bioimplant firm GenSci Regeneration Sciences. The firms will be targeting the bone void filler market, which was worth around $300m in 2002.
You may also be interested in...
Erectile problems prevent a quarter of Brits from being intimate with a partner. Viatris' Upjohn - which markets Viagra Connect in the UK - is working with the Men’s Health Forum, sexual health charity Brook and dating expert Sarah Louise Ryan raise awareness of the problem and get men talking about the issue with their partners and with healthcare professionals.
Medtechs took a long look at themselves as they rose to the challenges of COVID-19. How they responded, repurposed and regrouped to tackle the coronavirus was both sobering and uplifting. The lessons of 2020 must be integrated into the digitally-enabled health care systems of 2021 and beyond.
Top 100 Review: The Calm Before The Storm – But Some Medtechs Already Reflect The Ravages Of COVID-19
2019 saw fewer revenues-boosting major acquisitions by top-tier medtechs. Companies that reported after the calendar year-end were the first to see the consequences of the pandemic on their annual figures.